How to Reduce Hematocrit Levels Naturally and Medically

Lowering a high hematocrit depends almost entirely on why it is elevated in the first place. Dehydration, smoking, sleep apnea, living at high altitude, testosterone therapy, and blood cancers like polycythemia vera can all push hematocrit above normal ranges, and each cause calls for a different strategy. Some people need nothing more than better hydration habits; others require regular blood draws, prescription medications, or treatment of an underlying condition. The approach that works is the one matched to the root problem.

Why the Cause Matters More Than the Number

Hematocrit is simply the percentage of your blood volume occupied by red blood cells. When that percentage climbs too high, blood becomes thicker, and thicker blood is harder for the heart to pump and more prone to clotting. But researchers have found that the relationship between hematocrit and clotting risk is not as straightforward as it sounds. Thrombosis does not accompany most types of erythrocytosis (the medical umbrella term for too many red blood cells), which means the danger depends heavily on the specific condition driving the rise, not just the number on your lab report.¹ A person whose hematocrit is elevated because they are dehydrated after a long flight faces a different situation from someone with polycythemia vera, a bone marrow disorder that causes uncontrolled red blood cell production.

This distinction matters practically because some interventions are aggressive and carry their own risks, like iron deficiency from repeated phlebotomy. Using a heavy-handed treatment for a mild or reversible cause can create problems that are worse than the original elevation. So the first step before any intervention is figuring out what is driving the numbers up.

Staying Well Hydrated

The simplest and most overlooked reason for a high hematocrit reading is dehydration. When your plasma volume drops, red blood cells become a larger share of total blood volume by default, even though the actual number of red cells has not changed. This is sometimes called “relative erythrocytosis” because the elevation is an illusion created by fluid loss rather than overproduction of red cells.

Research on hydration and blood composition confirms this relationship in real-world conditions. A study on prolonged exercise in hot conditions showed that participants who received no fluids experienced the greatest drop in plasma volume, while those given an isotonic drink actually maintained or slightly increased their plasma volume, with significant differences between the two groups.² And in a clinical study of patients with diabetes, oral water hydration significantly lowered mean hematocrit values, with average readings dropping from about 39% before hydration to about 38% after.³

A one-percentage-point shift may sound tiny, but it illustrates the principle: if your hematocrit is borderline elevated and you are not drinking enough water, fixing that alone could bring the number back within range. People who drink coffee or alcohol heavily, work outdoors, or simply forget to drink water throughout the day are the most likely to show artificially high readings. Your doctor may ask you to repeat the blood draw after a few days of deliberate hydration before pursuing any further workup.

Quitting Smoking and Treating Oxygen Problems

Your body produces more red blood cells when it senses that tissues are not getting enough oxygen. This is the mechanism behind hematocrit elevations in smokers, people with sleep apnea, and those living at high altitude. The signal molecule erythropoietin (EPO) ramps up in response to low oxygen, telling the bone marrow to churn out additional red cells. Fixing the oxygen problem turns off that signal.

The evidence on smoking cessation is clear: in polycythemic patients who quit smoking, hemoglobin and hematocrit values dropped significantly within three months compared to baseline.⁴ That decrease was large enough that the authors concluded smoking cessation could reduce the need for more aggressive treatments like phlebotomy. But there is a wrinkle for smokers. Supplemental oxygen therapy in hypoxic patients with high hematocrit works well for nonsmokers, whose hematocrit dropped from around 57% to 48% in one study. Smokers, however, had only an incomplete response, falling from about 62% to 57%, because carbon monoxide from cigarettes occupies space on hemoglobin that oxygen cannot displace. The researchers concluded that to get a full response, hypoxic smokers need to quit, not just add supplemental oxygen on top of continued smoking.⁵

Sleep apnea works through a similar hypoxia pathway. A meta-analysis found that EPO levels are elevated in sleep apnea patients compared to normal subjects, especially in those with cardiovascular complications.⁶ In patients with severe sleep apnea, EPO increased by about 20% during untreated sleep, and that increase dropped after just four hours of CPAP treatment.⁷ If your hematocrit is elevated and you snore heavily, wake up gasping, or feel exhausted despite sleeping enough hours, a sleep study is worth pursuing. Treating the apnea treats the hematocrit problem at its root.

High Altitude and Chronic Mountain Sickness

People who live at high altitude develop higher hematocrit as a normal adaptation to thinner air, and for most this is harmless. But in some individuals, the response becomes excessive, a condition called chronic mountain sickness. Researchers tested three interventions in these patients. Descending from about 3,940 meters to 1,050 meters reduced total hemoglobin mass by roughly 16% within three weeks, a fast and dramatic response. Nighttime oxygen supplementation and daily acetazolamide (a medication that stimulates breathing) were also effective, though they reduced hemoglobin mass by only about 6%.⁸

Descent is the most effective option, but it is not practical for people whose livelihood depends on remaining at elevation. Acetazolamide and supplemental oxygen provide a compromise for those who cannot relocate. For visitors or seasonal workers who develop symptoms at altitude, simply returning to a lower elevation for a few weeks can normalize blood values.

How Regular Exercise Reshapes Blood Composition

Exercise has a counterintuitive effect on hematocrit. In the short term, intense exertion can concentrate the blood through sweating and fluid shifts, raising hematocrit temporarily. But with regular endurance training over months, the body expands its total blood volume, and it does so in a specific order: plasma volume increases first, diluting the red blood cells and transiently lowering hematocrit. Red blood cell volume follows later. Endurance athletes can have up to 40% more red blood cell volume than sedentary individuals, and regular training in healthy people can increase red blood cell volume by up to 10% over months, yet their hematocrit often stays in the normal or even low-normal range because plasma volume has expanded even more.⁹

What this means practically is that a sedentary person with mildly elevated hematocrit who starts a regular aerobic exercise program may see their hematocrit drift downward as their plasma volume expands. Exercise is not a targeted treatment for dangerously high levels, but for borderline readings, it is one more tool that shifts the balance in the right direction, on top of all its other health benefits.

Blood Donation and Therapeutic Phlebotomy

Removing blood directly is the fastest way to lower hematocrit. Each unit of whole blood removed reduces the red blood cell mass, and the body replaces the lost fluid (plasma) faster than it replaces the lost red cells, so hematocrit drops. This happens whether the blood is removed at a donation center or in a clinical setting.

For people with polycythemia vera, therapeutic phlebotomy is the foundation of treatment. All patients should receive phlebotomy with a target hematocrit below 45%, along with low-dose aspirin if they have no contraindications.¹⁰ This threshold is not arbitrary; a landmark trial showed that patients maintained below 45% had significantly fewer cardiovascular events than those kept at a higher target.

Voluntary blood donation is sometimes used by people on testosterone therapy whose hematocrit rises. However, research raises concerns about this approach as a standalone solution. One study found that repeat blood donation was not enough to keep hematocrit below 54% in testosterone therapy patients, and the authors warned about a false sense of security: both patients and providers sometimes assume donation has eliminated the vascular risk when it has not.¹¹ A separate multi-center study confirmed that more frequent donations were associated with lower hematocrit readings, but also with significant drops in ferritin, which is the body’s iron storage protein.¹² Depleted iron stores bring their own set of problems, including fatigue and poor concentration.

Cytoreductive Medications for Polycythemia Vera

When phlebotomy alone cannot keep hematocrit under control, or when patients have additional risk factors, doctors add medications that slow down the bone marrow’s production of blood cells. Hydroxyurea has been the standard first-line drug for decades. It is cheap, well-studied, and effective for most patients. But some people develop intolerance or stop responding.

Ruxolitinib, a JAK inhibitor, is approved as a second-line option in those situations. In a randomized trial comparing ruxolitinib to standard therapy (which could include hydroxyurea, interferon, or other agents), hematocrit control was achieved in 60% of patients on ruxolitinib versus 20% on standard therapy. Complete blood count remission rates and symptom improvement were also substantially better with ruxolitinib.¹³ Real-world clinical data have been similarly encouraging, with roughly 88% of patients achieving hematocrit control by three months of treatment.¹⁴ A European observational study found durable results at two years as well, with over 92% of patients maintaining hematocrit below 45% and the vast majority no longer needing phlebotomy at all.¹⁵

These drugs are not used for every type of hematocrit elevation. Cytoreductive therapy is reserved for polycythemia vera and similar myeloproliferative conditions. If your hematocrit is high because of dehydration or sleep apnea, no one is going to prescribe ruxolitinib.

ACE Inhibitors and ARBs

A less well-known hematocrit-lowering effect comes from a class of blood pressure medications. ACE inhibitors and angiotensin receptor blockers (ARBs) interfere with the renin-angiotensin system, which plays a role in stimulating red blood cell production. A dose-dependent decrease in hematocrit is typically observed within the first month of therapy, with values stabilizing at a lower level by about three months.¹⁶

For most people with high blood pressure, the hematocrit drop is small and clinically unimportant. But in certain situations, such as post-transplant erythrocytosis or secondary polycythemia from chronic lung disease, the effect can be profound enough to be therapeutically useful. A large observational analysis of over 14,000 patients found that consistent use of ACE inhibitors was associated with greater reductions in hemoglobin compared to calcium channel blockers, and that higher doses carried higher odds of developing anemia.¹⁷ In patients with heart failure, enalapril increased the odds of developing anemia by about 50% within one year.¹⁸

Nobody prescribes an ACE inhibitor purely to lower hematocrit. But if you already need blood pressure treatment and also have an elevated hematocrit, choosing an ACE inhibitor or ARB over a different antihypertensive can address both problems simultaneously. This is one of those situations where the side effect of a medication becomes a therapeutic benefit in the right patient.

When Testosterone Therapy Pushes Hematocrit Up

Increases in hemoglobin and hematocrit are the most common side effect of testosterone replacement therapy (TRT) in men being treated for low testosterone.¹⁹ Testosterone directly stimulates EPO production and enhances iron absorption, both of which drive red blood cell production. The degree of hematocrit elevation depends partly on the delivery method. Injectable testosterone, especially long-acting depot formulations, tends to produce sharper peaks in testosterone levels and correspondingly larger hematocrit spikes than gels, patches, or newer oral formulations. A narrative review found that the route of administration strongly influences the extent of hematocrit increases, and that choosing the right preparation can minimize the problem.²⁰

If your hematocrit has risen because of TRT, your doctor has several options before telling you to stop therapy altogether. Switching from injections to a transdermal gel or patch often blunts the rise. Lowering the dose is another common first step. If those adjustments are not enough, phlebotomy can buy time, though as noted earlier, blood donation alone may not keep hematocrit consistently below a safe threshold. In some cases, the most responsible option is discontinuing testosterone, particularly if hematocrit rises above 54% and cannot be brought down by other means.

Medications That Can Raise Hematocrit

While most of this article covers how to bring hematocrit down, it is worth knowing which medications can push it up, since recognizing a medication-related cause can simplify management. Beyond testosterone, a growing class of diabetes drugs called SGLT2 inhibitors also raises hematocrit. A meta-analysis found that SGLT2 inhibitors significantly increased hematocrit by an average of about 2.3 percentage points compared to placebo or other diabetes treatments.²¹ The mechanism is different from testosterone: SGLT2 inhibitors cause the kidneys to excrete more glucose and water, concentrating the blood, while also appearing to stimulate EPO production.

The irony is that this hematocrit rise may actually be part of why SGLT2 inhibitors protect the heart and kidneys. Researchers have proposed that the mild hemoconcentration improves oxygen delivery to tissues. For most patients, this increase is harmless and even beneficial. But for someone whose hematocrit is already elevated from another cause, the additive effect could push values into a concerning range. If you are starting an SGLT2 inhibitor and your baseline hematocrit is already on the high side, this is something to discuss with your prescriber so monitoring can be adjusted.

When Lowering Hematocrit Goes Too Far

Aggressive treatment of elevated hematocrit carries its own risks, and the most common one is iron deficiency. Patients with polycythemia vera frequently already have low iron at diagnosis because their overactive bone marrow consumes iron faster than they can absorb it. Repeated phlebotomy makes this worse, producing symptoms like persistent fatigue, difficulty concentrating, and general lethargy that significantly diminish quality of life.²²

This creates a paradox for clinicians: the iron deficiency eventually limits the bone marrow’s ability to make red blood cells, which is partly how phlebotomy works. But the symptoms of iron depletion can be miserable. Patients sometimes feel worse after their hematocrit is controlled than they did when it was high. The standard approach is to avoid iron supplementation in polycythemia vera patients (since giving iron would fuel more red cell production), but clinicians increasingly recognize that symptom management in these patients needs to account for iron status, not just hematocrit targets.

For people whose hematocrit elevation is mild and secondary to a reversible cause, overtreatment is an unnecessary risk. A mildly dehydrated person does not need phlebotomy. Someone whose sleep apnea is about to be treated with CPAP does not need cytoreductive drugs. Matching the intensity of the intervention to the severity and cause of the elevation is the thread running through all of these approaches, and it is the most important principle to keep in mind.